222 related articles for article (PubMed ID: 21823919)
1. Depot-medroxyprogesterone acetate contraception use among Salvadoran women: an in-depth analysis of attitudes and experiences.
Cremer M; Ditzian L; April A; Peralta E; Klausner D; Podolsky R; Dierking E
J Womens Health (Larchmt); 2011 Nov; 20(11):1751-6. PubMed ID: 21823919
[TBL] [Abstract][Full Text] [Related]
2. A cross-sectional study of the forearm bone mineral density in long-term current users of the injectable contraceptive depot medroxyprogesterone acetate.
Viola AS; Castro S; Bahamondes MV; Fernandes A; Viola CF; Bahamondes L
Contraception; 2011 Nov; 84(5):e31-7. PubMed ID: 22018135
[TBL] [Abstract][Full Text] [Related]
3. Depo Provera. Position paper on clinical use, effectiveness and side effects.
Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
[TBL] [Abstract][Full Text] [Related]
4. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
Steinauer JE; Upadhyay UD; Sokoloff A; Harper CC; Diedrich JT; Drey EA
Contraception; 2015 Dec; 92(6):553-9. PubMed ID: 26093190
[TBL] [Abstract][Full Text] [Related]
5. Attitudes toward long-acting reversible contraception among young women seeking abortion.
Rose SB; Cooper AJ; Baker NK; Lawton B
J Womens Health (Larchmt); 2011 Nov; 20(11):1729-35. PubMed ID: 21923281
[TBL] [Abstract][Full Text] [Related]
6. Pharmacist-administered subcutaneous depot medroxyprogesterone acetate: a pilot randomized controlled trial.
Picardo C; Ferreri S
Contraception; 2010 Aug; 82(2):160-7. PubMed ID: 20654757
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of injectable contraceptive users in a low-income population in Texas.
Sangi-Haghpeykar H; Poindexter AN; Moseley DC; Bateman L; Reid ED
Fam Plann Perspect; 1995; 27(5):208-11, 225. PubMed ID: 9104608
[TBL] [Abstract][Full Text] [Related]
8. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians.
Kaunitz AM
Int J Fertil Womens Med; 1998; 43(2):73-83. PubMed ID: 9609206
[TBL] [Abstract][Full Text] [Related]
9. Long-acting contraceptive options.
Kaunitz AM
Int J Fertil Menopausal Stud; 1996; 41(2):69-76. PubMed ID: 8829701
[TBL] [Abstract][Full Text] [Related]
10. Counseling issues and management of side effects for women using depot medroxyprogesterone acetate contraception.
Nelson AL
J Reprod Med; 1996 May; 41(5 Suppl):391-400. PubMed ID: 8725701
[TBL] [Abstract][Full Text] [Related]
11. Implanon users are less likely to be satisfied with their contraception after 6 months than IUD users.
Wong RC; Bell RJ; Thunuguntla K; McNamee K; Vollenhoven B
Contraception; 2009 Nov; 80(5):452-6. PubMed ID: 19835719
[TBL] [Abstract][Full Text] [Related]
12. Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes.
Westhoff C
J Reprod Med; 1996 May; 41(5 Suppl):401-6. PubMed ID: 8725702
[TBL] [Abstract][Full Text] [Related]
13. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer.
Kaunitz AM
J Reprod Med; 1996 May; 41(5 Suppl):419-27. PubMed ID: 8725705
[TBL] [Abstract][Full Text] [Related]
14. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population.
Polaneczky M; Guarnaccia M; Alon J; Wiley J
Fam Plann Perspect; 1996; 28(4):174-8. PubMed ID: 8853283
[TBL] [Abstract][Full Text] [Related]
15. The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women.
Scholes D; LaCroix AZ; Ichikawa LE; Barlow WE; Ott SM
Contraception; 2004 Feb; 69(2):99-104. PubMed ID: 14759613
[TBL] [Abstract][Full Text] [Related]
16. Human vaginal histology in long-term users of the injectable contraceptive depot-medroxyprogesterone acetate.
Bahamondes MV; Castro S; Marchi NM; Marcovici M; Andrade LA; Fernandes A; Bahamondes L
Contraception; 2014 Aug; 90(2):117-22. PubMed ID: 24613369
[TBL] [Abstract][Full Text] [Related]
17. Use of depot medroxyprogesterone acetate contraception in adolescents.
Davis AJ
J Reprod Med; 1996 May; 41(5 Suppl):407-13. PubMed ID: 8725703
[TBL] [Abstract][Full Text] [Related]
18. Correlates of use of long-acting reversible methods of contraception among adolescent and young adult women.
Whitaker AK; Dude AM; Neustadt A; Gilliam ML
Contraception; 2010 Apr; 81(4):299-303. PubMed ID: 20227545
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of users of intrauterine devices and other reversible contraceptive methods in the United States.
Xu X; Macaluso M; Frost J; Anderson JE; Curtis K; Grosse SD
Fertil Steril; 2011 Nov; 96(5):1138-44. PubMed ID: 21917255
[TBL] [Abstract][Full Text] [Related]
20. Bone mineral density in women using depot medroxyprogesterone acetate (DMPA) for at least 2 years compared to a control group: a cross sectional study.
Pongsatha S; Ekmahachai M; Chaovisitsaree S; Suntornlimsiri N; Morakote N
J Med Assoc Thai; 2009 Oct; 92(10):1263-7. PubMed ID: 19845231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
